DK1701698T3 - Direkte komprimerbart farmaceutisk præparat til oral indgivelse af CCI-779 - Google Patents

Direkte komprimerbart farmaceutisk præparat til oral indgivelse af CCI-779

Info

Publication number: DK1701698T3
Authority: DK; Denmark
Prior art keywords: cci; pharmaceutical composition; oral administration; directly compressible; compressible pharmaceutical
Prior art date: 2004-01-08

Application number

DK04814371T

Other languages

English (en)

Inventor

Muhammad Ashraf

Eric J Benjamin

Original Assignee

Wyeth Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-01-08

Filing date

2004-12-14

Publication date

2008-05-05

2004-12-14 Application filed by Wyeth Corp filed Critical Wyeth Corp

2008-05-05 Application granted granted Critical

2008-05-05 Publication of DK1701698T3 publication Critical patent/DK1701698T3/da

Links

CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
229960000235 temsirolimus Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Oncology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

DK04814371T 2004-01-08 2004-12-14 Direkte komprimerbart farmaceutisk præparat til oral indgivelse af CCI-779 DK1701698T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US53495104P	2004-01-08	2004-01-08
PCT/US2004/042178 WO2005070393A2 (en)	2004-01-08	2004-12-14	Directly compressible pharmaceutical composition of the rapamycin ester cci-779

Publications (1)

Publication Number	Publication Date
DK1701698T3 true DK1701698T3 (da)	2008-05-05

Family

ID=34806893

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK04814371T DK1701698T3 (da)	2004-01-08	2004-12-14	Direkte komprimerbart farmaceutisk præparat til oral indgivelse af CCI-779

Country Status (30)

Country	Link
US (1)	US20050152983A1 (da)
EP (1)	EP1701698B1 (da)
JP (1)	JP2007517879A (da)
KR (1)	KR20060130162A (da)
CN (1)	CN1921861A (da)
AR (1)	AR047180A1 (da)
AT (1)	ATE383859T1 (da)
AU (1)	AU2004314213A1 (da)
BR (1)	BRPI0418373A (da)
CA (1)	CA2552595A1 (da)
CR (1)	CR8491A (da)
CY (1)	CY1107373T1 (da)
DE (1)	DE602004011398T2 (da)
DK (1)	DK1701698T3 (da)
EC (1)	ECSP066757A (da)
ES (1)	ES2298861T3 (da)
GT (1)	GT200500003A (da)
HN (1)	HN2005000005A (da)
IL (1)	IL176519A0 (da)
MX (1)	MXPA06007829A (da)
NO (1)	NO20062930L (da)
PA (1)	PA8621201A1 (da)
PE (1)	PE20050683A1 (da)
PL (1)	PL1701698T3 (da)
PT (1)	PT1701698E (da)
RU (1)	RU2006122517A (da)
TW (1)	TW200526213A (da)
UA (1)	UA84903C2 (da)
WO (1)	WO2005070393A2 (da)
ZA (1)	ZA200605631B (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2345999C2 (ru)	2003-09-03	2009-02-10	Уайт	Аморфный 42-эфир рапамицина и 3-гидрокси-2(гидроксиметил)-2-метилпропионовой кислоты и содержащие его фармацевтические композиции
JP4224115B2 (ja) *	2004-04-14	2009-02-12	ワイス	ラパマイシン４２−エステル誘導体の位置特異的合成
CA2562164A1 (en) *	2004-04-27	2005-11-10	Wyeth	Labeling of rapamycin using rapamycin-specific methylases
EP1855656A2 (en) *	2005-02-15	2007-11-21	Wyeth	Orally bioavailable cci-779 tablet formulations
CA2629714A1 (en)	2005-11-14	2007-05-24	Ariad Gene Therapeutics, Inc.	Administration of an mtor inhibitor to treat patients with cancer
JP5475443B2 (ja) *	2006-06-28	2014-04-16	エミスフェアー・テクノロジーズ・インク	硝酸ガリウム製剤
US8430055B2 (en)	2008-08-29	2013-04-30	Lutonix, Inc.	Methods and apparatuses for coating balloon catheters
US20080276935A1 (en)	2006-11-20	2008-11-13	Lixiao Wang	Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US9700704B2 (en)	2006-11-20	2017-07-11	Lutonix, Inc.	Drug releasing coatings for balloon catheters
US8414525B2 (en)	2006-11-20	2013-04-09	Lutonix, Inc.	Drug releasing coatings for medical devices
US8414909B2 (en)	2006-11-20	2013-04-09	Lutonix, Inc.	Drug releasing coatings for medical devices
US9737640B2 (en)	2006-11-20	2017-08-22	Lutonix, Inc.	Drug releasing coatings for medical devices
US8414526B2 (en)	2006-11-20	2013-04-09	Lutonix, Inc.	Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8998846B2 (en)	2006-11-20	2015-04-07	Lutonix, Inc.	Drug releasing coatings for balloon catheters
US8425459B2 (en)	2006-11-20	2013-04-23	Lutonix, Inc.	Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US8414910B2 (en)	2006-11-20	2013-04-09	Lutonix, Inc.	Drug releasing coatings for medical devices
WO2011151704A2 (en)	2010-06-02	2011-12-08	Fresenius Kabi Oncology Ltd.	Stable pharmaceutical compositions of rapamycin esters
CN107898791A (zh)	2010-06-03	2018-04-13	药品循环有限责任公司	布鲁顿酪氨酸激酶(btk)抑制剂的应用
JO3754B1 (ar)	2012-06-04	2021-01-31	Pharmacyclics Llc	أشكال كريستالين لمثبط أنزيم كيناز تيروسين بروتون
CN104704129A (zh)	2012-07-24	2015-06-10	药品循环公司	与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变
US10682415B2 (en)	2013-07-22	2020-06-16	Wisconsin Alumni Research Foundation	Thermogel formulation for combination drug delivery
CN104721158B (zh) *	2013-12-24	2018-01-30	正大天晴药业集团股份有限公司	一种稳定的依维莫司片剂
IL315294A (en)	2015-03-03	2024-10-01	Pharmacyclics Llc	Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
WO2017038925A1 (ja) *	2015-09-03	2017-03-09	日本化薬株式会社	ラパマイシン又はその誘導体を含有する医薬組成物
WO2017129772A1 (en)	2016-01-29	2017-08-03	Xellia Phamaceuticals Aps	Stable pharmaceutical compositions of temsirolimus

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA737247B (en) *	1972-09-29	1975-04-30	Ayerst Mckenna & Harrison	Rapamycin and process of preparation
JP2642486B2 (ja) *	1989-08-04	1997-08-20	田辺製薬株式会社	難溶性薬物の超微粒子化法
US5536729A (en) *	1993-09-30	1996-07-16	American Home Products Corporation	Rapamycin formulations for oral administration
US5928668A (en) *	1993-12-21	1999-07-27	Applied Analytical Industries, Inc.	Method for dry blend compression of medicaments
US5362718A (en) *	1994-04-18	1994-11-08	American Home Products Corporation	Rapamycin hydroxyesters
BE1009856A5 (fr) *	1995-07-14	1997-10-07	Sandoz Sa	Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
RU2186562C2 (ru) *	1996-08-22	2002-08-10	Ресеч Трайангл Фармасьютикалс Лтд.	Композиции, представляющие собой микрочастицы веществ, нерастворимых в воде, и способ их изготовления
US5989591A (en) *	1997-03-14	1999-11-23	American Home Products Corporation	Rapamycin formulations for oral administration
US5985325A (en) *	1997-06-13	1999-11-16	American Home Products Corporation	Rapamycin formulations for oral administration
US6277983B1 (en) *	2000-09-27	2001-08-21	American Home Products Corporation	Regioselective synthesis of rapamycin derivatives
TWI286074B (en) *	2000-11-15	2007-09-01	Wyeth Corp	Pharmaceutical composition containing CCI-779 as an antineoplastic agent
UA77200C2 (en) *	2001-08-07	2006-11-15	Wyeth Corp	Antineoplastic combination of cci-779 and bkb-569
DE60324609D1 (de) *	2002-09-17	2008-12-18	Wyeth Corp	GRANULIERTE FORMULIERUNG DES RAPAMYCINESTERS CCl-779
UA83484C2 (uk) *	2003-03-05	2008-07-25	Уайт	Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
CN1829514A (zh) *	2003-07-25	2006-09-06	惠氏公司	Cci－779冻干制剂
KR20060057605A (ko) *	2003-08-07	2006-05-26	와이어쓰	Ｃｃｉ-779의 위치선택적 합성 방법
RU2345999C2 (ru) *	2003-09-03	2009-02-10	Уайт	Аморфный 42-эфир рапамицина и 3-гидрокси-2(гидроксиметил)-2-метилпропионовой кислоты и содержащие его фармацевтические композиции
US20060142422A1 (en) *	2004-12-07	2006-06-29	Toshikazu Kobayashi	Hydrolysis resistant polyester compositions and articles made therefrom
EP1855656A2 (en) *	2005-02-15	2007-11-21	Wyeth	Orally bioavailable cci-779 tablet formulations

2004
- 2004-12-14 JP JP2006549291A patent/JP2007517879A/ja not_active Withdrawn
- 2004-12-14 PL PL04814371T patent/PL1701698T3/pl unknown
- 2004-12-14 BR BRPI0418373-8A patent/BRPI0418373A/pt not_active IP Right Cessation
- 2004-12-14 PT PT04814371T patent/PT1701698E/pt unknown
- 2004-12-14 DK DK04814371T patent/DK1701698T3/da active
- 2004-12-14 KR KR1020067015655A patent/KR20060130162A/ko not_active Ceased
- 2004-12-14 CN CNA2004800399872A patent/CN1921861A/zh active Pending
- 2004-12-14 WO PCT/US2004/042178 patent/WO2005070393A2/en not_active Ceased
- 2004-12-14 MX MXPA06007829A patent/MXPA06007829A/es active IP Right Grant
- 2004-12-14 ES ES04814371T patent/ES2298861T3/es not_active Expired - Lifetime
- 2004-12-14 RU RU2006122517/15A patent/RU2006122517A/ru not_active Application Discontinuation
- 2004-12-14 AT AT04814371T patent/ATE383859T1/de not_active IP Right Cessation
- 2004-12-14 EP EP04814371A patent/EP1701698B1/en not_active Expired - Lifetime
- 2004-12-14 DE DE602004011398T patent/DE602004011398T2/de not_active Expired - Lifetime
- 2004-12-14 UA UAA200608870A patent/UA84903C2/ru unknown
- 2004-12-14 CA CA002552595A patent/CA2552595A1/en not_active Abandoned
- 2004-12-14 AU AU2004314213A patent/AU2004314213A1/en not_active Abandoned
- 2004-12-27 TW TW093140750A patent/TW200526213A/zh unknown
2005
- 2005-01-04 AR ARP050100016A patent/AR047180A1/es not_active Application Discontinuation
- 2005-01-05 GT GT200500003A patent/GT200500003A/es unknown
- 2005-01-06 HN HN2005000005A patent/HN2005000005A/es unknown
- 2005-01-06 PE PE2005000043A patent/PE20050683A1/es not_active Application Discontinuation
- 2005-01-06 US US11/030,685 patent/US20050152983A1/en not_active Abandoned
- 2005-01-07 PA PA20058621201A patent/PA8621201A1/es unknown
2006
- 2006-06-22 IL IL176519A patent/IL176519A0/en unknown
- 2006-06-22 NO NO20062930A patent/NO20062930L/no not_active Application Discontinuation
- 2006-06-28 CR CR8491A patent/CR8491A/es not_active Application Discontinuation
- 2006-07-07 ZA ZA200605631A patent/ZA200605631B/xx unknown
- 2006-08-08 EC EC2006006757A patent/ECSP066757A/es unknown
2008
- 2008-03-31 CY CY20081100359T patent/CY1107373T1/el unknown

Also Published As

Publication number	Publication date
GT200500003A (es)	2005-08-18
ES2298861T3 (es)	2008-05-16
PA8621201A1 (es)	2005-12-23
ZA200605631B (en)	2010-01-27
KR20060130162A (ko)	2006-12-18
AR047180A1 (es)	2006-01-11
PT1701698E (pt)	2008-03-27
MXPA06007829A (es)	2006-09-01
RU2006122517A (ru)	2008-02-20
PE20050683A1 (es)	2005-11-04
HN2005000005A (es)	2009-04-17
AU2004314213A1 (en)	2005-08-04
PL1701698T3 (pl)	2008-03-31
CR8491A (es)	2008-08-21
CN1921861A (zh)	2007-02-28
NO20062930L (no)	2006-10-02
ECSP066757A (es)	2006-11-16
DE602004011398D1 (de)	2008-03-06
WO2005070393A2 (en)	2005-08-04
UA84903C2 (ru)	2008-12-10
US20050152983A1 (en)	2005-07-14
EP1701698B1 (en)	2008-01-16
HK1090308A1 (en)	2006-12-22
WO2005070393A3 (en)	2006-09-28
DE602004011398T2 (de)	2009-01-15
CA2552595A1 (en)	2005-08-04
TW200526213A (en)	2005-08-16
CY1107373T1 (el)	2012-12-19
ATE383859T1 (de)	2008-02-15
BRPI0418373A (pt)	2007-05-22
EP1701698A2 (en)	2006-09-20
JP2007517879A (ja)	2007-07-05
IL176519A0 (en)	2006-10-05

Publication	Publication Date	Title
DK1701698T3 (da)	2008-05-05	Direkte komprimerbart farmaceutisk præparat til oral indgivelse af CCI-779
DK2172205T3 (da)	2014-07-14	Farmaceutisk formulering bestående af lanthan-forbindelser
DK2058020T3 (da)	2013-01-07	Indretning til indgivelse af lægemiddel
BRPI0511900A (pt)	2008-01-22	composições farmacêuticas
DK2361609T3 (da)	2013-08-26	Formulering af småmolekylære lægemidler med forsinket frigivelse
DK1928405T3 (da)	2014-12-15	Farmaceutiske sammensætninger til behandling af indre øreforstyrrelser
DK1656347T3 (da)	2011-01-10	Substituerede indolderivater til farmaceutisk sammensætning til behandling af luftvejssygdomme
DK2292219T3 (da)	2013-06-24	Transdermalt terapeutisk system til administration af rivastigmin
DK1601359T3 (da)	2009-01-05	Væskeformige, farmaceutiske formuleringer af palonosetron
DK1587478T3 (da)	2013-10-21	Farmaceutisk sammensætning
DK1725218T3 (da)	2014-09-01	Farmaceutisk sammensætning omfattende pimobendan
BRPI0716698A2 (pt)	2014-02-25	Composto, composição farmacêutica e uso de um composto
EP1799271A4 (en)	2010-05-05	DISPOSAL OF POLYNUCLEOTIDES
SK4325U (sk)	2005-12-01	Farmaceutická kompozícia s postupným uvoľňovaním
DE60317803D1 (de)	2008-01-10	Pharmazeutische zusammensetzungen enthaltend cyclosporin zur oralen verabreichung
DK3072507T3 (da)	2021-02-08	Farmaceutiske sammensætninger til glukokortikoidsubstitutionsterapi
DK1798234T3 (da)	2012-08-27	Farmaceutisk sammensætning omfattende temozolomidester
DK1617827T3 (da)	2008-06-02	Farmaceutisk sammensætning i form af en hydrogel til den transdermale administration af aktivstoffer
EP1714648A4 (en)	2010-05-26	COMBINATION DRUGS
SE0400685D0 (sv)	2004-03-19	Means for transdermal administration of nicotine
DK1474114T3 (da)	2010-04-12	Oral doseringsform til reguleret frigivelse af et lægemiddel
PT1752164E (pt)	2014-07-30	Preparação farmacêutica percutânea para uso externo contendo analgésico anti-inflamatório não esteroide
ITMI20041447A1 (it)	2004-10-20	Composizione farmaceutica comprendente gabapentina
DK1691808T3 (da)	2009-08-03	Farmeceutisk sammensætning til oral indgivelse af et pyrazol-3-carboxamid
DK1646373T3 (da)	2008-12-15	Orodispergerbar farmaceutisk sammensætning af en antithrombotisk forbindelse